Post-translational modification-governed immune states in cancer immunity: Biomarker implications for checkpoint competence, tumor visibility and immunotherapy resistance (Review)
Immune escape and therapeutic resistance remain major obstacles to durable benefit from cancer immunotherapy, yet transcript-based or abundance-based biomarkers often fail to capture the regulatory states that determine effective immune control. Post-translational modifications (PTMs) form a dynamic protein-state layer...